Recent Finacing
Recent Raise
Affigen develops cell-lineage-specific tumor-identifying therapeutics, leveraging immuno-oncology and mass-personalized biomolecular engineering to advance lead programs from preclinical studies into Phase 1 trials for hematologic malignancies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor